You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2015MP1-20 DISTINGUISHING INDOLENT FROM AGGRESSIVE PROSTATE CANCER IN ACTIVE SURVEILLANCE USING PARTIALWAVE SPECTROSCOPY TO MEASURE NANOCYTOLOGICAL FIELD CARCINOGENESIS James Kearns, Brian Helfand, Charles Brendler, Hemant Roy, Chi-Hsiung Wang, Kristian Novakovic, Hariharan Subramanian, Di Zhang, Charles Maneval, and Vadim Backman James KearnsJames Kearns More articles by this author , Brian HelfandBrian Helfand More articles by this author , Charles BrendlerCharles Brendler More articles by this author , Hemant RoyHemant Roy More articles by this author , Chi-Hsiung WangChi-Hsiung Wang More articles by this author , Kristian NovakovicKristian Novakovic More articles by this author , Hariharan SubramanianHariharan Subramanian More articles by this author , Di ZhangDi Zhang More articles by this author , Charles ManevalCharles Maneval More articles by this author , and Vadim BackmanVadim Backman More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.183AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Field carcinogenesis (FC) is a well-documented phenomenon that occurs in prostate cancer (PC). We have developed a novel biophotonics technology, partial wave spectroscopic (PWS) microscopy, or nanocytology, which quantifies intranuclear organization beyond the limits of conventional light microscopy. Our previous data within 7 other cancers has demonstrated that PWS-detected alterations in histologically normal cells are a highly accurate biomarker of FC, cancer risk, and disease aggressiveness. We hypothesized that PWS could be used to distinguish aggressive disease PC patients undergoing active surveillance (AS). METHODS PWS nanocytology was performed on core tissue samples obtained on the initial surveillance biopsy from 38 men undergoing AS. PWS was performed on histologically normal prostatic epithelium that was not adjacent to the cancerous tissue. The “disorder length” (Ld) was measured in 40 glandular epithelial cells for each sample. Patients were grouped by clinical outcomes stratified by success or failure of AS for 3 years. RESULTS The baseline clinical characteristics of men were not significantly different between progressors (n=20) and non-progressors (n=18) and included: mean age 66.5±5.6 years, mean BMI of 28.1±4.0, median PSA of 4.73ng/ml, and mean prostate volume of 42.5 ±20.7mL. Using PWS, the Ld was found to be significantly increased in the progressors compared to nonprogressors (p=0.002). This was associated with an effect size of 110% with 80% sensitivity and 85% specificity. CONCLUSIONS PWS nanocytological assessment of FC can predict disease progression in AS. This novel technology has the potential to mitigate overtreatment of PC. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e9 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information James Kearns More articles by this author Brian Helfand More articles by this author Charles Brendler More articles by this author Hemant Roy More articles by this author Chi-Hsiung Wang More articles by this author Kristian Novakovic More articles by this author Hariharan Subramanian More articles by this author Di Zhang More articles by this author Charles Maneval More articles by this author Vadim Backman More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...